TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

KILL Teva Announces Launch of Generic Epzicom® Tablets in the United States

Teva Pharmaceutical Industries Ltd. requests that their press release NewsItemId: 20160928005512 entitled “Teva Announces Launch of Generic Epzicom® Tablets in the United States” be killed.

The release was issued by Teva Pharmaceutical Industries Ltd. without final FDA approval.

A replacement release will be issued at a later time.

EN
28/09/2016

Underlying

TEVA.NTeva Pharmaceutical Industries Limited Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Bi...

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industri...

December 19, 2025 1 EN
Free Trial
TEVA.N Teva Pharmaceut...

Teva Pharmaceutical Industries Ltd: 2 directors

Two Directors at Teva Pharmaceutical Industries Ltd sold 89,700 shares at between 30.204USD and 30.241USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's ...

TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
12/18/25 December 18, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva Releases Q4 2025 Aide Memoire

Teva Releases Q4 2025 Aide Memoire TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website. Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of fourth quarter 2025 results, which are expected to be released on Wednesday, January 28, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva’s prior results, management’s previous co...

December 12, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial ...

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance to obtain a local or toll-free phone number and your personal pin...

December 12, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapin...

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population1Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia1Teva is committed to advancing this innovative treatment option and f...

December 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch